This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
In just a few short years, glucagon-like peptide-1 (GLP-1) receptor agonists have surged in popularity across the United States, transforming from specialized treatments for type 2 diabetes into revolutionary therapeutics for weight management, cardiovascular health and other emerging uses. But not all populations are benefiting from this expansion. As GLP-1 use has increased, disparities in access to these drugs have widened significantly, according to a new study led by researchers at Boston University School of Public Health (BUSPH).
Published in the journal Health Affairs Scholar, the study found that the percentage of patients with overweight or obesity and without type 2 diabetes who filled prescriptions for semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound) within six months of becoming eligible surged from 1.9% in 2021 to 16.6% in 2025.
But prescriptions for these medications were lower among men, Black or Hispanic patients, younger or older patients (ages 18–34 or 55–64), patients in a lower BMI category and/or patients whose health care provider was located in a neighborhood with lower socioeconomic status (SES), measured by education levels in the provider's ZIP code.
These disparities widened over time and were particularly pronounced in 2024 and 2025, after semaglutide and tirzepatide received formal approval by the Food and Drug Administration for chronic weight management in 2021 and 2023, respectively.
By mimicking a natural hormone that helps regulate insulin, blood sugar, appetite and digestion, GLP-1s can help people achieve dramatic weight loss, particularly those who struggle to lose weight through traditional diet and exercise.
Source link







